Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Available 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Non-Muscle Invasive Bladder Neoplasms 2Urologic Neoplasms 1Urinary Bladder Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma in Situ 1

Interventions

Sunitinib 2tucatinib 1testosterone 17 beta-cypionate 1pembrolizumab 1dodecyl maltoside 1cabozantinib 1Urinary Diversion 1Trastuzumab 1Testosterone Propionate 1Standard of Care 1Saline Solution 1Radiosurgery 1Psychiatric Nursing 1Practice Guidelines as Topic 1Physical Therapy Modalities 1Methyltestosterone 1Lidocaine 1Immune Checkpoint Inhibitors 1Fulvestrant 1Doxycycline 1Cystectomy 1Control Groups 1Ado-Trastuzumab Emtansine 11-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Urologic Neoplasms × dodecyl maltoside × Clear all
NCT06111235 2026-01-12

A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

CG Oncology, Inc.

Phase 3 Active not recruiting
367 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡